| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Steno Diabetes Center and Hagedorn Research Institute (S.K.H., E.-M.D.N., J.E., G.A., C.G., B.C., K.B.-J., T.H., O.P.), Gentofte, Copenhagen, Denmark; Research Center for Prevention and Health, Copenhagen County, Glostrup University Hospital (C.G., T.D., K.B.-J., T.J.), Glostrup, Denmark; Exiqon A/S (P.M.), Vedbæk, Denmark; and Faculty of Health Science, University of Aarhus (K.B.-J., O.P.), Aarhus, Denmark
Address all correspondence and requests for reprints to: Professor Oluf Pedersen, M.D., D.M.Sc., Steno Diabetes Center and Hagedorn Research Institute, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark. E-mail: oluf{at}steno.dk.
The separate and combined effects of the PPARG Pro12Ala polymorphism and the KCNJ11 Glu23Lys polymorphisms on risk of type 2 diabetes were investigated in relatively large-scale, case-control studies. Separate effects of the variants were examined among 1187/1461 type 2 diabetic patients and 4791/4986 middle-aged, glucose-tolerant subjects. The combined analysis involved 1164 type 2 diabetic patients and 4733 middle-aged, glucose-tolerant subjects. In the separate analyses, the K allele of the KCNJ11 Glu23Lys associated with type 2 diabetes (odds ratio, 1.19; P = 0.0002), whereas the PPARG Pro12Ala showed no significant association with type 2 diabetes. The combined analysis indicated that the two polymorphisms acted in an additive manner to increase the risk of type 2 diabetes, and we found no evidence for a synergistic interaction between them. Analysis of a model with equal additive effects of the two variants showed that the odds ratio for type 2 diabetes increased with 1.14/risk allele (P = 0.003). Together, the two polymorphisms conferred a population-attributable risk for type 2 diabetes of 28%. In conclusion, our results showed no evidence of a synergistic interaction between the KCNJ11 Glu23Lys and PPARG Pro12Ala polymorphisms, but indicated that they may act in an additive manner to increase the risk of type 2 diabetes.
This article has been cited by other articles:
![]() |
N. J. Webster, G. J. Searle, P. P. L. Lam, Y.-C. Huang, M. J. Riedel, G. Harb, H. Y. Gaisano, A. Holt, and P. E. Light Elevation in Intracellular Long-Chain Acyl-Coenzyme A Esters Lead to Reduced {beta}-Cell Excitability via Activation of Adenosine 5'-Triphosphate-Sensitive Potassium Channels Endocrinology, July 1, 2008; 149(7): 3679 - 3687. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yi, L. Dongmei, D. A. Phares, E. P. Weiss, J. Brandauer, and J. M. Hagberg Association between KCNJ11 E23K genotype and cardiovascular and glucose metabolism phenotypes in older men and women Exp Physiol, January 1, 2008; 93(1): 95 - 103. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Taylor, J. M. Norris, and J. I. Rotter Genome-Wide Association: Which Do You Want First: the Good News, the Bad News, or the Good News? Diabetes, December 1, 2007; 56(12): 2844 - 2848. [Full Text] [PDF] |
||||
![]() |
Y. Doi, M. Kubo, T. Ninomiya, K. Yonemoto, M. Iwase, H. Arima, J. Hata, Y. Tanizaki, M. Iida, and Y. Kiyohara Impact of Kir6.2 E23K Polymorphism on the Development of Type 2 Diabetes in a General Japanese Population: The Hisayama Study Diabetes, November 1, 2007; 56(11): 2829 - 2833. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Scott, L. L. Bonnycastle, C. J. Willer, A. G. Sprau, A. U. Jackson, N. Narisu, W. L. Duren, P. S. Chines, H. M. Stringham, M. R. Erdos, et al. Association of Transcription Factor 7-Like 2 (TCF7L2) Variants With Type 2 Diabetes in a Finnish Sample Diabetes, September 1, 2006; 55(9): 2649 - 2653. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sesti, E. Laratta, M. Cardellini, F. Andreozzi, S. Del Guerra, C. Irace, A. Gnasso, M. Grupillo, R. Lauro, M. L. Hribal, et al. The E23K Variant of KCNJ11 Encoding the Pancreatic {beta}-Cell Adenosine 5'-Triphosphate-Sensitive Potassium Channel Subunit Kir6.2 Is Associated with an Increased Risk of Secondary Failure to Sulfonylurea in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2334 - 2339. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |